<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">34981049</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2021.12.03.471045</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2021.12.03.471045</ELocationID><Abstract><AbstractText>On the 24 <sup>th</sup> November 2021 the sequence of a new SARS CoV-2 viral isolate spreading rapidly in Southern Africa was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titres of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic as well as Alpha, Beta, Gamma, Delta are substantially reduced or fail to neutralize. Titres against Omicron are boosted by third vaccine doses and are high in cases both vaccinated and infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of a large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses, combining mutations conferring tight binding to ACE2 to unleash evolution driven by immune escape, leading to a large number of mutations in the ACE2 binding site which rebalance receptor affinity to that of early pandemic viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dejnirattisai</LastName><ForeName>Wanwisa</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Jiandong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Daming</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zahradn&#xed;k</LastName><ForeName>Ji&#x159;&#xed;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Supasa</LastName><ForeName>Piyada</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duyvesteyn</LastName><ForeName>Helen M E</ForeName><Initials>HME</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginn</LastName><ForeName>Helen M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Diamond Light Source Ltd, Harwell Science &amp; Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentzer</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuekprakhon</LastName><ForeName>Aekkachai</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nutalai</LastName><ForeName>Rungtiwa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Beibei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dijokaite</LastName><ForeName>Aiste</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Suman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avinoam</LastName><ForeName>Ori</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahar</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skelly</LastName><ForeName>Donal</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adele</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sile Ann</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amini</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritter</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dold</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Sciences, University of Leicester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assadi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellass</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omo-Dare</LastName><ForeName>Nikki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeckerling</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Sciences Division, University of Oxford.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaxman</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aley</LastName><ForeName>Parvinder K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voysey</LastName><ForeName>Merryn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clemens</LastName><ForeName>Sue Ann Costa</ForeName><Initials>SAC</Initials><AffiliationInfo><Affiliation>Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naveca</LastName><ForeName>Felipe Gomes</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ecologia de Doen&#xe7;as Transmiss&#xed;veis na Amaz&#xf4;nia, Instituto Le&#xf4;nidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Valdinete</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ecologia de Doen&#xe7;as Transmiss&#xed;veis na Amaz&#xf4;nia, Instituto Le&#xf4;nidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laborat&#xf3;rio de Ecologia de Doen&#xe7;as Transmiss&#xed;veis na Amaz&#xf4;nia, Instituto Le&#xf4;nidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes da Costa</LastName><ForeName>Cristiano</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Funda&#xe7;&#xe3;o de Vigil&#xe2;ncia em Sa&#xfa;de do Amazonas, Manaus, Amazonas, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Resende</LastName><ForeName>Paola Cristina</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Laboratorio de v&#xed;rus respirat&#xf3;rios- IOC/FIOCRUZ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauvolid-Correa</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratorio de v&#xed;rus respirat&#xf3;rios- IOC/FIOCRUZ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterinary Integrative Biosciences, Texas A&amp;M University, College Station, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siqueira</LastName><ForeName>Marilda M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Laboratorio de v&#xed;rus respirat&#xf3;rios- IOC/FIOCRUZ, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baillie</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serafin</LastName><ForeName>Natali</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ditse</LastName><ForeName>Zanele</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Silva</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhi</LastName><ForeName>Shabir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Marta C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Openshaw</LastName><ForeName>Peter Jm</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>National Heart &amp; Lung Institute, Imperial College London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baillie</LastName><ForeName>J Kenneth</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Genetics and Genomics, Roslin Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semple</LastName><ForeName>Malcolm G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>NIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Townsend</LastName><ForeName>Alain R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Kuan-Ying A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Tiong Kit</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Miles W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klenerman</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Eleanor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunachie</LastName><ForeName>Susanna J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Medawar Building for Pathogen Research, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand, Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantinides</LastName><ForeName>Bede</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Hermione</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crook</LastName><ForeName>Derrick</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollard</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambe</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OPTIC consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>ISARIC4C consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Paterson</LastName><ForeName>Neil G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Diamond Light Source Ltd, Harwell Science &amp; Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Diamond Light Source Ltd, Harwell Science &amp; Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Diamond Light Source Ltd, Harwell Science &amp; Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fry</LastName><ForeName>Elizabeth E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mongkolsapaya</LastName><ForeName>Juthathip</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Siriraj Center of Research Excellence in Dengue &amp; Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Jingshan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>Gideon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuart</LastName><ForeName>David I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Diamond Light Source Ltd, Harwell Science &amp; Innovation Campus, Didcot, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Screaton</LastName><ForeName>Gavin R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_19025</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_19059</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_20060</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V028448/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Cell. 2022 Feb 3;185(3):467-484.e15</RefSource><PMID Version="1">35081335</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Competing Financial Interests. G.R.S sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. J.Z. and G.S. declare the Israel patent application no. 23/09/2020 &#x2013; 277546 and U.S.A patent application no. 16/12/2020 &#x2013; 63/125,984, entitled Methods and compositions for treating coronaviral infections. Oxford University holds intellectual property related to the Oxford-AstraZeneca vaccine. AJP is Chair of UK Dept. Health and Social Care&#x2019;s (DHSC) Joint Committee on Vaccination &amp; Immunisation (JCVI) but does not participate in the JCVI COVID19 committee, and is a member of the WHO&#x2019;s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. The University of Oxford has entered into a partnership with AstraZeneca on coronavirus vaccine development. The University of Oxford has protected intellectual property disclosed in this publication. S.C.G. is co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and is named as an inventor on a patent covering use of ChAdOx1-vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). T.L. is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an unrelated project during the conduct of the study. S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34981049</ArticleId><ArticleId IdType="pmc">PMC8722586</ArticleId><ArticleId IdType="doi">10.1101/2021.12.03.471045</ArticleId><ArticleId IdType="pii">2021.12.03.471045</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acharya R., Fry E., Stuart D., Fox G., Rowlands D., and Brown F. (1989). The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature 337, 709&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">2537470</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes C.O., Jette C.A., Abernathy M.E., Dam K.A., Esswein S.R., Gristick H.B., Malyutin A.G., Sharaf N.G., Huey-Tubman K.E., Lee Y.E., et al. (2020). SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. (2020). Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton D.J., Wrobel A.G., Xu P., Roustan C., Martin S.R., Rosenthal P.B., Skehel J.J., and Gamblin S.J. (2020). Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116727</ArticleId><ArticleId IdType="pubmed">32942285</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameroni E., Saliba C., Bowen J.E., Rosen L.E., Culap K., Pinto D., De Marco A., Zepeda S.K., di Lulio J., Zatta F., et al. (2021). Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv 2021.12.12.472269; doi: 10.1101/2021.12.12.472269</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.12.472269</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Karim F., Lustig G., San J.E., Hermanus T., Tegally H., Snyman J., Moyo-Gwete T., Wilkinson E., M. B., et al. (2021). SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity. medRxiv 2021.09.14.21263564; doi: 10.1101/2021.09.14.21263564</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.14.21263564</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G., Guo Y., Zhou T., Gorman J., Lee M., Rapp M., Reddem E.R., Yu J., Bahna F., Bimela J., et al. (2021). Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe 29, 819&#x2013;833 e817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi X., Yan R., Zhang J., Zhang G., Zhang Y., Hao M., Zhang Z., Fan P., Dong Y., Yang Y., et al. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 369, 650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7319273</ArticleId><ArticleId IdType="pubmed">32571838</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark S.A., Clark L.E., Pan J., Coscia A., McKay L.G.A., Shankar S., Johnson R.I., Brusic V., Choudhary M.C., Regan J., et al. (2021). SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 184, 2605&#x2013;2617 e2618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962548</ArticleId><ArticleId IdType="pubmed">33831372</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Khait R., and Schreiber G. (2016). Low-stringency selection of TEM1 for BLIP shows interface plasticity and selection for faster binders. Proc Natl Acad Sci U S A 113, 14982&#x2013;14987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206572</ArticleId><ArticleId IdType="pubmed">27956635</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmenares-Mejia C.C., Serrano-Diaz N., Quintero-Lesmes D.C., Meneses L., Salazar Acosta I., Idrovo A.J., Sanabria-Echeverry D.Y., Cordero-Rebolledo H., and Castillo V. (2021). Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia. Int J Environ Res Public Health 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8071134</ArticleId><ArticleId IdType="pubmed">33920843</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Zhou D., Ginn H.M., Duyvesteyn H.M.E., Supasa P., Case J.B., Zhao Y., Walter T.S., Mentzer A.J., Liu C., et al. (2021a). The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell 184, 2183&#x2013;2200 e2122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891125</ArticleId><ArticleId IdType="pubmed">33756110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Zhou D., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. (2021b). Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939&#x2013;2954 e2939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008340</ArticleId><ArticleId IdType="pubmed">33852911</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J., Zost S., Greaney A., Starr T.N., Dingens A.S., Chen E.C., Chen R., Case B., Sutton R., Gilchuk P., et al. (2021). Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv 2021.01.27.428529; doi: 10.1101/2021.01.27.428529</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.01.27.428529</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbe S., and Buckland-Merrett G. (2017). Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall 1, 33&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6607375</ArticleId><ArticleId IdType="pubmed">31565258</ArticleId></ArticleIdList></Reference><Reference><Citation>Emsley P., Lohkamp B., Scott W.G., and Cowtan K. (2010). Features and development of Coot. Acta Crystallographica Section D: Biological Crystallography 66, 486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2852313</ArticleId><ArticleId IdType="pubmed">20383002</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman A., Marchevsky N.G., Jenkin D., Aboagye J., Aley P.K., Angus B., Belij-Rammerstorfer S., Bibi S., Bittaye M., Cappuccini F., et al. (2021). Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398, 981&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409975</ArticleId><ArticleId IdType="pubmed">34480858</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Qin B., Chen P., Zhu K., Hou P., Wojdyla J.A., Wang M., and Cui S. (2021). Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B 11, 237&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467110</ArticleId><ArticleId IdType="pubmed">32895623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L., et al. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie K.M., Li H., Bedinger D., Schendel S.L., Dennison S.M., Li K., Rayaprolu V., Yu X., Mann C., Zandonatti M., et al. (2021). Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science 374, 472&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302186</ArticleId><ArticleId IdType="pubmed">34554826</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J., Zhao Y., Ren J., Zhou D., Duyvesteyn H.M.E., Ginn H.M., Carrique L., Malinauskas T., Ruza R.R., Shah P.N.M., et al. (2020). Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. Cell Host Microbe 28, 445&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7303615</ArticleId><ArticleId IdType="pubmed">32585135</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Zidek A., Potapenko A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature 596, 583&#x2013;589 (2021). 10.1038/s41586-021-03819-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim F., Moosa M.Y.S., Gosnell B.I., Cele S., Giandhari J., Pillay S., Tegally H., Wilkinson E., San J.E., Msomi N., et al. (2021). Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv 2021.06.03.21258228; doi: 10.1101/2021.06.03.21258228</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.03.21258228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Z., Oton J., Qu K., Cortese M., Zila V., McKeane L., Nakane T., Zivanov J., Neufeldt C.J., Cerikan B., et al. (2020). Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature 588, 498&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116492</ArticleId><ArticleId IdType="pubmed">32805734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., Collier D.A., Datir R.P., Ferreira I., Gayed S., Jahun A., Hosmillo M., Rees-Spear C., Mlcochova P., Lumb I.U., et al. (2021). SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Krissinel E., and Henrick K. (2007). Protein interfaces, surfaces and assemblies service PISA at European Bioinformatics Institute. J Mol Biol 372, 774&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">17681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebschner D., Afonine P.V., Baker M.L., Bunkoczi G., Chen V.B., Croll T.I., Hintze B., Hung L.W., Jain S., McCoy A.J., et al. (2019). Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol 75, 861&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778852</ArticleId><ArticleId IdType="pubmed">31588918</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Ginn H.M., Dejnirattisai W., Supasa P., Wang B., Tuekprakhon A., Nutalai R., Zhou D., Mentzer A.J., Zhao Y., et al. (2021a). Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220&#x2013;4236 e4213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218332</ArticleId><ArticleId IdType="pubmed">34242578</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Zhou D., Nutalai R., Duyvestyn H., Tuekprakhon A., Ginn H., Dejnirattisai W., Supasa P., Mentzer A., Wang B., et al. (2021b). The Beta mAb response underscores the antigenic distance to other SARS-CoV-2 variants. Cell, Host and Microbe.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626228</ArticleId><ArticleId IdType="pubmed">34921776</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Soh W.T., Kishikawa J.I., Hirose M., Nakayama E.E., Li S., Sasai M., Suzuki T., Tada A., Arakawa A., et al. (2021c). An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell 184, 3452&#x2013;3466 e3418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142859</ArticleId><ArticleId IdType="pubmed">34139176</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin D.P., Weaver S., Tegally H., San J.E., Shank S.D., Wilkinson E., Lucaci A.G., Giandhari J., Naidoo S., Pillay Y., et al. (2021). The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. Cell 184, 5189&#x2013;5200 e5187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8421097</ArticleId><ArticleId IdType="pubmed">34537136</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., and Read R.J. (2007). Phaser crystallographic software. J Appl Crystallogr 40, 658&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483472</ArticleId><ArticleId IdType="pubmed">19461840</ArticleId></ArticleIdList></Reference><Reference><Citation>Moeller N.H., Shi K., Demir O., Banerjee S., Yin L., Belica C., Durfee C., Amaro R.E., and Aihara H. (2021). Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. bioRxiv 2021.04.02.438274; doi: 10.1101/2021.04.02.438274</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.02.438274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen J.L., Tsueng G., Latif A.A., Alkuzweny M., Cano M., Haag E., Zhou J., Zeller M., Hufbauer E., Matteson N., et al. (2020). Center for Viral Systems Biology outbreak.info.</Citation></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J., et al. (2021). An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science, eabl4784.</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Peleg Y., and Unger T. (2014). Application of the Restriction-Free (RF) cloning for multicomponents assembly. Methods Mol Biol 1116, 73&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">24395358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Meng E.C., Couch G.S., Croll T.I., Morris J.H., and Ferrin T.E. (2021). UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci 30, 70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D., Park Y.J., Beltramello M., Walls A.C., Tortorici M.A., Bianchi S., Jaconi S., Culap K., Zatta F., De Marco A., et al. (2020). Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A., Holmes E.C., O'Toole A., Hill V., McCrone J.T., Ruis C., du Plessis L., and Pybus O.G. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 5, 1403&#x2013;1407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp M., Guo Y., Reddem E.R., Yu J., Liu L., Wang P., Cerutti G., Katsamba P., Bimela J.S., Bahna F.A., et al. (2021). Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1&#x2013;2-derived antibody class. Cell Rep 35, 108950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7972811</ArticleId><ArticleId IdType="pubmed">33794145</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert X., and Gouet P. (2014). Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42, W320&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086106</ArticleId><ArticleId IdType="pubmed">24753421</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G., Arnold E., Erickson J.W., Frankenberger E.A., Griffith J.P., Hecht H.J., Johnson J.E., Kamer G., Luo M., Mosser A.G., et al. (1985). Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317, 145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert M., Bertoglio F., Steinke S., Heine P.A., Ynga-Durand A., Zuo F., Du L., Kom J., Milosevic M., Wenzel E.V., et al. (2021). Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants. medRxiv 2021.12.10.21267523; doi: 10.1101/2021.12.10.21267523</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.10.21267523</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Dingens A.S., and Bloom J.D. (2021). Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 Cell Reports Medicine, 2, 100255, ISSN 2666&#x2013;3791, 10.1016/j.xcrm.2021.100255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100255</ArticleId><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr T.N., Greaney A.J., Hilton S.K., Ellis D., Crawford K.H.D., Dingens A.S., Navarro M.J., Bowen J.E., Tortorici M.A., Walls A.C., et al. (2020). Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 182, 1295&#x2013;1310 e1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418704</ArticleId><ArticleId IdType="pubmed">32841599</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart D.I., Levine M., Muirhead H., and Stammers D.K. (1979). Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. J Mol Biol 134, 109&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">537059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., and Ho M. (2020). Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. Antib Ther 3, 246&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717131</ArticleId><ArticleId IdType="pubmed">33912795</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Wang L., Feng R., Wang N., Wang Y., Zhu D., Xing X., Yang P., Zhang Y., Li W., et al. (2021). Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms. Cell Res 31, 597&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005859</ArticleId><ArticleId IdType="pubmed">33782529</ArticleId></ArticleIdList></Reference><Reference><Citation>Supasa P., Zhou D., Dejnirattisai W., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Nutalai R., Tuekprakhon A., et al. (2021). Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201&#x2013;2211 e2207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891044</ArticleId><ArticleId IdType="pubmed">33743891</ArticleId></ArticleIdList></Reference><Reference><Citation>Toelzer C., Gupta K., Yadav S.K.N., Borucu U., Davidson A.D., Kavanagh Williamson M., Shoemark D.K., Garzoni F., Staufer O., Milligan R., et al. (2020). Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science 370, 725&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050947</ArticleId><ArticleId IdType="pubmed">32958580</ArticleId></ArticleIdList></Reference><Reference><Citation>Valesano A.L., Rumfelt K.E., Dimcheff D.E., Blair C.N., Fitzsimmons W.J., Petrie J.G., Martin E.T., and Lauring A.S. (2021). Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts. PLoS Pathog 17, e1009499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055005</ArticleId><ArticleId IdType="pubmed">33826681</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., and Veesler D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181, 281&#x2013;292 e286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Tortorici M.A., Snijder J., Xiong X., Bosch B.J., Rey F.A., and Veesler D. (2017). Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A 114, 11157&#x2013;11162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651768</ArticleId><ArticleId IdType="pubmed">29073020</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter T.S., Diprose J., Brown J., Pickford M., Owens R.J., Stuart D.I., and Harlos K. (2003). A procedure for setting up high-throughput nanolitre crystallization experiments. I. Protocol design and validation. Journal of Applied Crystallography 36, 308&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159505</ArticleId><ArticleId IdType="pubmed">15930615</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich D.M., Sivapalasingam S., Norton T., Ali S., Gao H., Bhore R., Musser B.J., Soo Y., Rofail D., Im J., et al. (2021). REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 384, 238&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7781102</ArticleId><ArticleId IdType="pubmed">33332778</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter G. (2010). xia2: an expert system for macromolecular crystallography data reduction. Journal of applied crystallography 43, 186&#x2013;190.</Citation></Reference><Reference><Citation>Winter G., Waterman D.G., Parkhurst J.M., Brewster A.S., Gildea R.J., Gerstel M., Fuentes-Montero L., Vollmar M., Michels-Clark T., Young I.D., et al. (2018). DIALS: implementation and evaluation of a new integration package. Acta Crystallogr D Struct Biol 74, 85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947772</ArticleId><ArticleId IdType="pubmed">29533234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong L.Y., Zheng J., Wilhelmsen K., Li K., Ortiz M.E., Schnicker N.J., Pezzulo A.A., Szachowicz P.J., Klumpp K., Aswad F., et al. (2021). Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19. bioRxiv 2021.04.20.440676; doi: 10.1101/2021.04.20.440676</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.20.440676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., and McLellan J.S. (2020). Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science. 2020 Mar 13;367(6483):1260&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Liu H., Wu N.C., Lee C.D., Zhu X., Zhao F., Huang D., Yu W., Hua Y., Tien H., et al. (2020). Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402627</ArticleId><ArticleId IdType="pubmed">32661058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahradnik J., Dey D., Marciano S., Kolarova L., Charendoff C.I., Subtil A., and Schreiber G. (2021a). A Protein-Engineered, Enhanced Yeast Display Platform for Rapid Evolution of Challenging Targets. ACS Synth Biol. 10, 3445&#x2013;3460</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689690</ArticleId><ArticleId IdType="pubmed">34809429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahradnik J., Marciano S., Shemesh M., Zoler E., Harari D., Chiaravalli J., Meyer B., Rudich Y., Li C., Marton I., et al. (2021b). SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol 6, 1188&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pubmed">34400835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahradnik J., Nunvar J., and Schreiber G. (2021c). SARS-CoV-2 convergent evolution as a guide to explore adaptive advantage. bioRxiv 2021.05.24.445534; doi: 10.1101/2021.05.24.445534</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.24.445534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Dejnirattisai W., Supasa P., Liu C., Mentzer A.J., Ginn H.M., Zhao Y., Duyvesteyn H.M.E., Tuekprakhon A., Nutalai R., et al. (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348&#x2013;2361 e2346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901269</ArticleId><ArticleId IdType="pubmed">33730597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Duyvesteyn H.M.E., Chen C.P., Huang C.G., Chen T.H., Shih S.R., Lin Y.C., Cheng C.Y., Cheng S.H., Huang Y.C., et al. (2020). Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature structural &amp; molecular biology 27, 950&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">32737466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zost S.J., Gilchuk P., Case J.B., Binshtein E., Chen R.E., Nkolola J.P., Schafer A., Reidy J.X., Trivette A., Nargi R.S., et al. (2020). Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584396</ArticleId><ArticleId IdType="pubmed">32668443</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>